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Abstract
Background: The mucopolysaccharidoses (MPSs) are lysosomal storage disorders associated with progressive multi-
organ and skeletal abnormalities. Clinical manifestations can affect each of the five senses: hearing, vision, smell,
taste, and touch.
Main body of the abstract: On 24–26 May 2018, 46 specialists with expertise in managing symptoms of MPS and
experts specialized in evaluating and managing impairments in each one of the five senses gathered in Lisbon,
Portugal at the “MPS & the five senses” meeting to discuss how loss of one or multiple senses can affect activities
of daily living (ADL) and quality of life (QoL) in MPS patients and best practices in evaluating and managing the
loss of senses in these individuals. The meeting confirmed that MPS can affect the senses considerably, but how
these impairments affect ADL and overall QoL from a patient’s perspective remains unclear. A better insight may be
achieved by prospectively collecting patient-reported outcome (PRO) data internationally in a standardized way,
using a standard battery of tools. To identify relevant PRO tools, a systematic literature review and a selection of
existing published questionnaires, focused on adults with no intellectual delay, were performed after the meeting.
The search strategy identified 33 PRO tools for hearing, 30 for speech, 125 for vision, 49 for touch (including pain
and upper limb function), and 15 for smell/taste. A further selection was made based on several criteria, including
applicability/relevance for MPS, applicability in different countries (languages)/cultures, availability in English, ease of
use, validation, and normative data, resulting in a final set of 11 tools. In addition to these sense-specific PRO tools,
a general QoL tool, the EuroQol (EQ)-5D-5 L, was selected to assess overall QoL and reveal coping behaviors.
Short conclusion: MPS can affect each of the five senses, but current knowledge on the impact of sense
impairments on QoL/ADL in MPS patients remains limited. Collection of data in a standardized fashion using sense-
specific patient-reported outcome tools and a general QoL tool may fill the current knowledge gap.
Keywords: Hearing, Mucopolysaccharidosis, Patient-reported outcomes, Quality of life, Review, Senses, Smell, Taste,
Touch, Vision
Background
The mucopolysaccharidoses (MPSs) comprise a group of
lysosomal storage disorders caused by deficiencies in en-
zymes involved in the catabolism of glycosaminoglycans
(GAGs) [1]. Patients with MPS exhibit an array of
progressively worsening disease manifestations caused by
GAG accumulation in tissues and organs throughout the
body, including skeletal and joint abnormalities, cardiore-
spiratory disease, neurological disease, ocular abnormal-
ities, and hearing loss [1]. Currently, there are 11 distinct
subclasses of MPS disorders, each affecting a specific lyso-
somal hydrolase: MPS I (Hurler, Hurler-Scheie, and
Scheie syndrome), MPS II (Hunter syndrome), MPS III
(Sanfilippo syndrome, including subtypes MPS IIIA, IIIB,
IIIC, and IIID), MPS IV (Morquio syndrome, including
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subtypes IVA and IVB), MPS VI (Maroteaux-Lamy syn-
drome), MPS VII (Sly syndrome), and MPS IX [1]. The
GAGs that accumulate in these MPS subclasses differ
considerably with respect to length, sulfation patterns, and
other structural variations, leading to pathophysiological
differences [2]. Clinical presentations and progression
rates vary widely between and within MPS disorders.
The various clinical manifestations of MPS may con-
siderably affect each of the five senses: hearing, vision,
smell, taste, and touch [3–7]. However, little is known
on how patients perceive impairments in the senses and
how these affect activities of daily living (ADL) and qual-
ity of life (QoL). Patient-reported outcomes (PROs) that
assess functioning (ADL) and QoL are becoming in-
creasingly important in clinical practice and research to
supplement clinical disease markers, and provide im-
portant insight into how patients perceive their condi-
tion and cope with their disabilities on a daily basis [8].
The “MPS & the five senses” expert meeting was held
on 24–26 May 2018 in Lisbon, Portugal to discuss how
loss of one or multiple senses can affect ADL and QoL
in individuals with MPS, best approaches to evaluate loss
of senses using PRO tools, and management of loss of
senses in these individuals. A total of 46 specialists with
expertise in managing symptoms of MPS and experts
specialized in the evaluation and management of impair-
ments in each one of the five senses attended this meet-
ing; four adult patients with MPS testified about their
impairments and the impact these impairments have on
ADL and QoL.
The objectives of the present paper are to provide an
overview of the overall findings of the “MPS & the five
senses” meeting and to identify the most relevant PRO
tools for assessing impairment in the senses and their
impact on ADL/QoL in MPS patients.
Impairments in the five senses in MPS
Hearing and speech
Progressive hearing loss is a common feature of all MPS
disorders, and is mainly due to recurrent otitis media,
middle ear effusion, ossicle deformity, inner ear (coch-
lea) abnormalities and alterations in the auditory nerve
[3, 9]. While young children with MPS generally present
with conductive hearing loss, mixed hearing loss or pure
sensorineural hearing loss tends to develop later in life
as part of the natural history of MPS. Hearing impair-
ment, but also oral manifestations (enlargement of the
lips, tongue, and oral mucosa), abnormalities of the lar-
ynx and vocal tract, abnormal nerve function, rhinolalia,
and/or cognitive issues can complicate speech, language,
and communication [10, 11]. Untreated hearing loss may
also lead to cognitive impairment [12]. Hearing and
speech problems may affect social interactions and par-
ticipation, development and learning, work, and overall
QoL, and can have psychological consequences (e.g. de-
pression) [13, 14]. Communicative disabilities can also
considerably affect other people in the patient’s environ-
ment [14].
Because of the high prevalence of hearing impairment,
regular monitoring for hearing loss in individuals with
MPS is important. Hearing-specific questionnaires may
be useful to assess the impact of hearing impairment on
the patient’s QoL [13, 15]. Management of hearing loss
in this patient population (e.g. ventilation tube insertion,
hearing aids, cochlear implantation) depends on the type
of hearing loss (conductive, sensorineural, or mixed), the
degree of hearing loss, and age of onset. Ventilation
tubes do not always normalize hearing in MPS patients
with conductive hearing loss [16]; clinicians should not
delay considering hearing aids for these patients. Reports
about the effect of hearing aids and cochlear implants in
patients with MPS are sparse [17]. Patients with speech
problems may also benefit from ventilation tube inser-
tion, amplification, and speech therapy [10].
Vision
Individuals with MPS frequently present with ocular
manifestations that can result in impaired vision and
even blindness [4, 18]. Although ocular features have
been described in all MPS disorders, they are particularly
common in MPS I, VI, and VII [4]. Typical ocular mani-
festations of MPS include corneal clouding, astigmatism
(mainly hyperopia), retinopathy, glaucoma, and optic
nerve abnormalities (optic disc swelling, optic nerve at-
rophy), amblyopia, strabismus, and possibly cerebral vis-
ual impairment [4, 18]. Morphological changes in the
eye generally develop very early in the disease course
and are often already present at the time of diagnosis
[18]. These alterations can be caused by excessive GAG
storage in the cornea, trabecular meshwork, iris, ciliary
body, retina, dura, sclera, optic nerve, extra-ocular mus-
cles, and/or posterior visual pathway [4].
Visual impairment and blindness can considerably
affect a patient’s independence, mobility, ADL, social in-
teractions, education, work, and overall QoL [19–21].
Regular eye exams in MPS patients are essential to de-
tect ocular abnormalities and allow proper management
in an early stage [4, 18]. In addition, vision-specific PRO
tools may provide information regarding potential im-
pairments in vision and their impact on the patient [22].
Corneal transplantation (keratoplasty) showed good out-
comes in MPS patients with corneal clouding, and
should be discussed and recommended to these patients
[23]. However, it should be noted that examination and
surgical management of ocular manifestations of MPS
can be challenging due to presence of masking concomi-
tant symptoms (e.g. masking of visual field changes asso-
ciated with glaucoma by superimposed visual field
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problems due to retinopathy), anesthetic risks, clinical
progression, and social isolation [4, 18]. Patients with
neurological decline or behavioral problems may be un-
able to cooperate in ophthalmological examinations [18].
Smell and taste
There are several clinical manifestations of MPS that
may cause impairments in smell and/or taste, i.e. ade-
noid hypertrophy, chronic rhinosinusitis, recurrent
upper respiratory tract infections, thickened nasal carti-
lages, macroglossia, dental defects (such as dental caries,
gingival inflammation, enamel hypoplasia, unerupted
teeth, hyperplastic tooth follicle, anterior open bite, and
condylar defects), and possibly neurodegenerative dis-
ease [5, 24–26]. In addition, continuous upper airway in-
fection can cause chronic production of infected mucus,
altering smell and taste. Tracheostomy, a procedure
often performed in MPS patients with progressed upper
airway disease, may give rise to impaired nasal function
[27]. However, there is a lack of publications describing
the impairments of smell and taste in patients with
MPS.
Olfactory dysfunction may negatively affect one’s ap-
petite, personal hygiene, social relationships, detection of
hazardous odors (e.g. smoke, gas), and ADL (e.g. cook-
ing), and may result in weight loss [28]. Therefore, it is
important that clinicians are aware of the potential pres-
ence of impaired nasal function in MPS patients. Impair-
ments in olfactory dysfunction can be identified using
odor identification, discrimination, and threshold levels
(e.g. using Sniffin’ Sticks) and PRO questionnaires [29].
Vaccinations, medical and surgical treatment of rhinosi-
nusitis, and nasal saline irrigation may prevent or im-
prove impairments in smell and taste in these patients
[30–32]. Hyperosmolar nasal sprays should be used with
caution, as experience with these sprays is mostly limited
to healthy individuals. In patients with swollen mucosae,
it may obstruct rather than free the nose [33]. It is im-
portant to be aware that adenoidectomy can be challen-
ging due to difficult airway access in patients with
limited neck extension, macroglossia and/or reduced
mouth opening, and the risk of atlanto-axial subluxation
[30].
Touch (including upper extremity function and pain)
Musculoskeletal disease involving the upper limbs (i.e.
skeletal and joint abnormalities), nerve compression syn-
dromes (i.e. carpal tunnel syndrome [CTS], ulnar nerve
entrapment [cubital tunnel syndrome], cervical cord
compression), and central nervous system changes can
result in impaired sensation and function of the upper
extremities in MPS patients [6, 7, 34–36]. Skeletal and
joint disease is particularly common in patients with
MPS I, IV and VI, but also occurs in the other MPS
disorders [35]. Typical skeletal findings in the upper ex-
tremities of MPS patients include bony and joint abnor-
malities in the fingers (claw hands, trigger finger) and
forearms, and restricted joint motion in fingers, elbows,
and shoulders [35, 37]. Wrist hypermobility is a typical
and unique manifestation of MPS IVA, resulting in lim-
ited control of the wrist and weak grip strength [7, 38].
CTS is caused by compression of the median nerve in
the carpal tunnel at the wrist, which is formed poster-
iorly by the carpal bones and anteriorly by the transverse
carpal ligament [34, 38]. Apart from the median nerve,
nine flexor tendons and their associated synovial sheaths
pass through the carpal tunnel. The median nerve inner-
vates five muscles in the hand: the first two lumbricals,
the opponens pollicis, the abductor pollicis brevis and
the flexor pollicis brevis. In MPS patients, CTS is gener-
ally caused by a combination of bone deformity, tenosy-
novial deposits, and GAG accumulation in the
connective tissue of the flexor retinaculum, and is most
common in MPS I, II, and VI [35, 39]. Typical signs are
burning pain, tingling and numbness in the thumb,
index and middle fingers, and the radial half of the ring
finger [34, 38]. Cervical cord compression most fre-
quently occurs in MPS I, IV, and VI and can be due to
atlanto-axial instability, bony stenosis secondary to mal-
formations of the spine and skull base, including odont-
oid dysplasia, or thickening of tissues surrounding the
spinal cord [35, 40, 41]. Cervical cord compression in
MPS patients may involve multiple levels, and can lead
to compressive myelopathy, which can manifest as weak-
ness, numbness, paresthesia, gait difficulty, and even par-
alysis or sudden death [39, 40].
Impaired sensation or pain and musculoskeletal abnor-
malities in the upper extremities may significantly affect
ADL and self-care, and can lead to limitations in activity
and social participation [7, 42]. CTS has been associated
with increased pain and reduced physical functioning
and overall QoL [43, 44], but evidence regarding the im-
pact of CTS in MPS patients on PROs is limited [45].
Impairments in upper extremity function and pain in
individuals with MPS can be evaluated using functional
tests (e.g. goniometry, pinch and grip strength, 9-hole
peg test), and/or PRO tools [8, 37, 46]. Diagnosing CTS
can be difficult in MPS patients as it often progresses
without typical symptoms, possibly due to masking
symptoms, communication problems, insidious onset,
and difficulties to perform nerve conduction studies due
to the patients’ unusually small hands, often young age,
and/or cognitive impairment [39, 47, 48]. Therefore,
regular monitoring is important to identify CTS. Nerve
ultrasound has been suggested as an alternative screen-
ing tool for CTS in these patients [47]. CTS can be
treated successfully with surgical release of the median
nerve, which should be performed before the median
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nerve is irreversibly damaged. Similarly, spinal cord
compression should be surgically treated as recom-
mended to prevent permanent damage to the spinal
cord, and taking into account the considerable
anesthetic risks in these patients [40, 41]. Pain can be
managed with cognitive-behavioral strategies (e.g. relax-
ation training), physical strategies (e.g. exercise, physical
activity), and pain medication [49–51].
Challenges for assessing impairments in the senses in MPS
Although it is clear that MPS can have a considerable
negative impact on each of the five senses, it remains
unclear how patients perceive these impairments and
how these affect their overall QoL. Literature on this
subject is very sparse, and PRO tools for assessing im-
pairments of the senses and their impact on QoL/ADL
are generally not part of routine clinical care of MPS pa-
tients. A voting round during the MPS & the five senses
meeting showed that only a minority of the attendees
currently use these kinds of PRO tools in MPS patients
in their practice. Nevertheless, PRO tools and physical
tests (e.g. audiology tests, visual acuity tests, goniometry)
can complement each other in decision-making for dis-
ease management. It is important to make a distinction
between health and how patients perceive their health,
which depends on how patients are coping with their
impairments.
A better insight into how MPS affects the senses and
how loss in one or more senses affects ADL and overall
QoL in patients with this disease can be achieved by
prospectively collecting data internationally in a stan-
dardized way, using a standard battery of tools. As inter-
actions between the senses are important, all senses
should be evaluated. It has been well established that
loss in one of the senses can lead to compensatory plas-
ticity and sharpening of other senses (e.g. enhanced
auditory abilities and tactile perception in blind individ-
uals [52, 53]). However, MPS patients with impairments
in multiple senses may not be able to compensate. In pa-
tients with loss in one of the senses, it becomes more
important to preserve functioning in the other senses. In
addition to using sense-specific PRO tools, it is import-
ant to evaluate patients using a general QoL tool to as-
sess overall QoL. This may reveal coping behaviors; i.e.
when a specific sense QoL tool shows impairment, an
overall QoL tool may present a score in the normal
range.
At the MPS & the five senses meeting, there was gen-
eral agreement that creating new or adapting existing
PRO tools specifically for MPS patients is difficult due
to the small patient number to test validity of these
tools. Instead, existing PRO tools could be useful for
evaluating these patients. However, selecting the most
appropriate PRO tools for MPS patients is extremely
challenging, because of the high number of available
tools. The following criteria were perceived most im-
portant: 1) applicability to patients with MPS, 2) applic-
ability to different countries (languages) and cultures, 3)
ease of use (≤10 min to complete), 4) validation, and 5)
availability of normative data.
With the above criteria in mind, the experts converged
on the use of the five-level EuroQol five-dimensional
questionnaire (EQ-5D-5 L) as the recommended general
QoL tool to document changes in QoL in patients with
MPS [54]. The EQ-5D-5 L is a simple and validated gen-
eric questionnaire that covers five dimensions of health:
Mobility, Self-care, Usual activities, Pain/Discomfort and
Anxiety/Depression. It is applicable to a wide range of
health conditions, and has also been used in a number
of studies involving patients with MPS [55–57]. Evalu-
ation with a general well-established QoL measure, such
as the EQ-5D-5 L, in combination with sense-specific
tools will provide a better picture on the impact of im-
pairments in the senses on QoL in MPS patients, and
will better guide management.
Selection of PRO tools for assessing the senses in MPS
After the meeting, a robust EMBASE literature search
was performed in June 2018 to identify different PRO
questionnaires used in other conditions related to the
five senses, that may also be useful in the evaluation of
sense impairments and their impact on QoL and/or
ADL in MPS patients (Supplementary file 1). The
searches were focused on tools for adult patients with
no intellectual delay, who are able to complete question-
naires themselves.
The search strategy yielded a total of 421 unique hits,
and identified a total of 33 tools for hearing, 30 for
speech, 125 for vision, 49 for touch (including pain and
upper limb function), and 15 for smell and taste. A se-
lection of these PRO tools was made based on several
criteria outlined in Supplementary file 1, including ap-
plicability/relevance for MPS, applicability in different
countries (languages)/cultures, availability in English,
ease of use, validation, and normative data. Table 1 pro-
vides an overview of the selected tools, including the
most relevant criteria.
Conclusions
MPS can lead to considerable impairments in each of
the five senses. However, current knowledge on the im-
pact of sense impairments on QoL/ADL in patients with
MPS remains very limited. Further research, i.e. collec-
tion of data in a standardized fashion using sense-
specific PRO tools (e.g. those summarized in Table 1)
and a general QoL tool such as the EQ-5D-5 L, is war-
ranted and may provide a better insight in how and to
what extent impairments in the senses affect ADL and
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Table 1 Overview of PRO tools suitable for assessing impairment in the senses and overall health status in patients with MPS, with
focus on adults and self-completion and based on the following criteria: applicability to patients with MPS, applicability to different
countries and cultures, ease of use (≤10 min to complete), validated, and availability of normative data
Name tool Abbreviation Original target
population
Time to
complete
What does it
measure?
Validation
literature
Normative data
literature
Used
in
MPS?
Language(s) Target
age
Hearing & speech
Hearing
Attitudes
Toward Loss of
Hearing
Questionnaire
ALHQ Hearing
impairment,
with or without
hearing aids
±10 min Attitudes toward
hearing loss and
hearing aids
Saunders
G 2005
[58]
Saunders G
2005 [58]
No English,
Korean
Adults
Spatial Hearing
Questionnaire
SHQ Not
disease-linked
±10 min Perception of
spatial hearing
abilities/
disabilities
Tyler RS
2009 [59]
Perreau AE
2014 [60]
No English + 10
translations
NA
Speech
Speech
Handicap
Index
SHI Speech
problems
5 min Speech-related
problems in daily
life (psychosocial
and speech
function)
Rinkel RN
2008 [61]
Rinkel RN
2008 [61]
No English,
French,
Dutch,
Portuguese,
Chinese
Adults
Voice
Handicap
Index
VHI Voice disorders 5 min Impact of voice
disorders on QoL
(functional,
physical and
emotional)
Francis
DO 2017
[62]
Arffa RE
2012 [63]
No English + 6
translations
Adults
Voice
Outcome
Survey
VOS Uncompensated
unilateral vocal
fold paralysis
2–5 min Vocal status and
impact on daily
activities
Gliklich
RE 1999 [64]
Gliklich RE
1999 [64]
English,
Chinese
Adults
Vision
Visual Function
Short Form
VF-8R Cataract 5 min Functional
impairment
caused by vision loss
Gothwal
VK 2010 [65]
Gothwal VK 2010
(pre- vs post-op)
[65]
No English,
Chinese
Adults
Touch
Upper limb function
Health
Assessment
Questionnaire
HAQ Arthritis 5 min Physical disability Bruce B
2003 [66]
Bruce B
2003 [66]
Yes
[8]a
English + 62
translations
Adultsd
Quick
Disabilities
of the Arm,
Shoulder
and Hand
Questionnaire
Quick-DASH Upper-extremity
disorders
2 min Symptoms and
ability to perform
certain activities
Beaton
DE 2005 [67]
Aasheim T
2014 [68]
No 50
languages
Adults
Pain
Brief Pain
Inventory
Short
Form
BPI-SF Chronic or
acute pain
5 min Pain severity and
impact of pain on
daily functioning
Cleeland
CS 2009
[69]
NAc Yes
[8]
English + 52
translations
Adults
West Haven -
Yale
Multidimensional
Pain Inventory
WHYMPI Chronic pain 5–10 min Description of
pain and how it
affects the
individual
Kerns RD
1985 [70]
https://www.va.gov/
PAINMANAGEMENT/
docs/
No English + 9
translations
Adults
Smell & taste
Chronic
Sinusitis
Surveyb
CSS Chronic
sinusitis
5 min Health status and
treatment
effectiveness in
chronic
rhinosinusitis
Gliklich
RE 1995
[71];
Stavem K
2006 [72]
Gliklich
RE 1997 [73]
No English,
Norwegian,
Chinese,
Turkish
Adults
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the patients’ overall QoL. The current selection focuses
on PRO tools for adults. However, as impairments in the
senses are also prevalent in children and adolescents
with MPS, it would be interesting to make a similar se-
lection of tools that might be suitable for these popula-
tions. This would allow investigators to better follow up
impairments in the senses in these patients over time
and take appropriate actions.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13023-020-01368-x.
Additional file 1. Details of literature search and selection of tools
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Name tool Abbreviation Original target
population
Time to
complete
What does it
measure?
Validation
literature
Normative data
literature
Used
in
MPS?
Language(s) Target
age
Health status
Five-level
EuroQol five-
dimensional
questionnaire
EQ-5D-5 L General
population
< 5min Generic measure
of health status
for clinical and
economic
appraisal
Herdman M
2011 [54]
Szende A
2014 [74]
Yes
[8]
> 120
languages
Adults
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NA Not available
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